Ware Olivia C
Insider CIK 1663771 · RVNC Director · ACLX Director · CTNM Director · CYTR Chief Commercial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics, In | A Award deriv | 2026-06-26 | 2026-06-26 | 19,000 | — | $0 | 19,000 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 11,459 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 8,011 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 9,174 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 36,806 | — | $0 | 0 | SEC↗ |
| CTNM Contineum Therapeutics, In | A Award deriv | 2025-06-26 | 2025-06-26 | 14,750 | — | $0 | 14,750 | SEC↗ |
| ACLX Arcellx, Inc. | A Award deriv | 2025-05-29 | 2025-05-30 | 9,174 | — | $0 | 9,174 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | D To issuer | 2025-02-06 | 2025-02-06 | 15,000 | — | $0 | 0 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | U Tender | 2025-02-04 | 2025-02-06 | 16,675 | $3.65 | $60.9K | 15,000 | SEC↗ |
| ACLX Arcellx, Inc. | A Award deriv | 2024-05-28 | 2024-06-06 | 8,011 | — | $0 | 8,011 | SEC↗ |
| CTNM Contineum Therapeutics, In | A Award deriv | 2024-05-24 | 2024-05-29 | 3,700 | — | $0 | 3,700 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award deriv | 2024-05-01 | 2024-05-03 | 23,458 | — | $0 | 23,458 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award | 2024-05-01 | 2024-05-03 | 15,000 | — | $0 | 31,675 | SEC↗ |
| ACLX Arcellx, Inc. | M Exercise deriv | 2024-04-16 | 2024-04-18 | 9,402 | — | $0 | 36,806 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2024-04-16 | 2024-04-18 | 6,790 | $55.36 | $375.9K | 2,612 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2024-04-16 | 2024-04-18 | 2,612 | $56.03 | $146.4K | 0 | SEC↗ |
| ACLX Arcellx, Inc. | M Exercise | 2024-04-16 | 2024-04-18 | 9,402 | $7.61 | $71.5K | 9,402 | SEC↗ |
| ACLX Arcellx, Inc. | M Exercise deriv | 2024-03-15 | 2024-03-18 | 9,000 | — | $0 | 46,208 | SEC↗ |
| ACLX Arcellx, Inc. | M Exercise | 2024-03-15 | 2024-03-18 | 9,000 | $7.61 | $68.5K | 9,000 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2024-03-15 | 2024-03-18 | 1,900 | $69.44 | $131.9K | 7,100 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2024-03-15 | 2024-03-18 | 3,763 | $70.36 | $264.8K | 3,337 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2024-03-15 | 2024-03-18 | 3,337 | $70.99 | $236.9K | 0 | SEC↗ |
| ACLX Arcellx, Inc. | A Award deriv | 2023-06-14 | 2023-06-16 | 11,459 | — | $0 | 11,459 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award deriv | 2023-05-03 | 2023-05-05 | 5,915 | — | $0 | 5,915 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award | 2023-05-03 | 2023-05-05 | 3,534 | — | $0 | 16,675 | SEC↗ |
| ACLX Arcellx, Inc. | A Award deriv | 2022-05-16 | 2022-05-17 | 55,208 | — | $0 | 55,208 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award deriv | 2022-05-04 | 2022-05-06 | 11,343 | — | $0 | 11,343 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award deriv | 2022-05-04 | 2022-05-13 | 10,756 | — | $0 | 10,756 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award | 2022-05-04 | 2022-05-06 | 6,059 | — | $0 | 13,141 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award deriv | 2021-05-05 | 2021-05-07 | 1,268 | — | $0 | 1,268 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award | 2021-05-05 | 2021-05-07 | 674 | — | $0 | 7,082 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award deriv | 2021-03-08 | 2021-03-10 | 11,161 | — | $0 | 11,161 | SEC↗ |
| RVNC Revance Therapeutics, Inc. | A Award | 2021-03-08 | 2021-03-10 | 6,408 | — | $0 | 6,408 | SEC↗ |
| CYTR CYTRX CORP | A Award deriv | 2016-01-11 | 2016-01-14 | 350,000 | — | $0 | 350,000 | SEC↗ |